Hodgkin Lymphoma – Epidemiology Forecast to 2029

2020-06-15
Price :
Published : Jun-2020
No. of Pages : 44

Hodgkin Lymphoma – Epidemiology Forecast to 2029

Summary

GlobalData epidemiologists used age- and sex-specific diagnosed incidence and prevalence rates to forecast the diagnosed incident and prevalent cases, taking into account the significant relationship between age and HL incidence. GlobalData epidemiologists applied country-specific incidence rates of HL, wherever available, to each country’s population to obtain the number of estimated diagnosed incident cases.

HL is a cancerous condition that affects the lymphatic system and occurs in both children and adults. HL is a rare disease that starts with abnormal growth of the white blood cells, called lymphocytes, and then spreads beyond the lymphatic system and impairs the body’s immune system. HL is classified into two main groups—cHL and NLPHL. cHL is further divided into subtypes, namely nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted. The classical form is the most frequently occurring HL, with almost 95% of HL cases belonging to the cHL type.

The following data describes epidemiology of HL cases. In 2019, the 8MM had 24,885 diagnosed incident cases of HL. This is expected to increase to 27,134 diagnosed incident cases by 2029, at an Annual Growth Rate (AGR) of 0.90%. This increase is partly attributed to the moderately rising trend in incidence in the 8MM, combined with underlying demographic changes in the respective markets. In the 8MM, the diagnosed incident cases of cHL will increase from 22,815 cases in 2019 to 24,820 cases in 2029, at an AGR of 0.88%, and the diagnosed incident cases of NLPHL will increase from 2,074 cases in 2019 to 2,314 cases in 2029, at an AGR of 1.18%. The development of more effective therapies, particularly for elderly patients, would improve survival from HL.

Scope

– Hodgkin Lymphoma (HL) Epidemiology Report provides an overview of the risk factors and global trends of Hodgkin Lymphoma in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Urban China).
– This report also includes a 10-year epidemiological forecast for the following segmentations in all ages across the 8MM: diagnosed incident cases of HL, classical HL (cHL), Nodular Lymphocyte Predominant HL (NLPHL); diagnosed incident cases of cHL segmented by sex and age, for all ages in 10-year age groups beginning at 0 years and ending at ?85 years; diagnosed five-year prevalent cases cHL; diagnosed incident cases of cHL by cancer staging (stage I -IV); and diagnosed incident cases of cHL by subtypes (nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted).
– The HL Epidemiology Report is written and developed by Masters- and PhD-level epidemiologists.
– The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

– The HL Epidemiology series will allow you to:
– Develop business strategies by understanding the trends shaping and driving the global HL, cHL, and NLPHL market.
– Quantify patient populations in the global HL market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the cHL cancer stages that present the best opportunities for cHL therapeutics in each of the markets covered.
– Understand magnitude of cHL market by subtypes.

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

Plasma Fractionation Market by Product (IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor), Application (Immunology, Hematology, Critical Care, Rheumatology, Pulmonology), End User (Hospitals & Clinics) – Global Forecast to 2025

 “Growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), and the growing prevalence of respiratory diseases and alpha-1-antitrypsin deficiency (AATD) is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 39.5 billion by 2025 from USD 28.6 billion in 2020, at a CAGR of 6.7% during the forecast period. Growth in the plasma fractionation market is primarily driven by factors such as growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), rising geriatric population, and the growing prevalence of respiratory diseases and alpha-1-ant......
$4950

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (Practice Management, e-Prescribing, PHM, Health Analytics, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User – Global Forecast to 2025

“Government support to increase adoption of EHR solutions is expected to drive the overall growth of the ambulatory EHR market.” The ambulatory EHR market is expected to reach USD 6.8 billion by 2025 from USD 5.2 billion in 2020, at a CAGR of 5.7% during the forecast period of 2020 to 2025. Growth in the global ambulatory EHR market can primarily be attributed to various factors such as government support for the adoption of EHR solutions, increasing number of outpatient care centers, growing patient volume due to the global outbreak of COVID-19, and the need to curtail healthcare costs. On the other hand, market growth is limited to a certain extent due to factors such as reluctance to adopt EHR solutions in developing countries, heavy infrastructure investments, and the high cost ......
$4950

Neisseria meningitidis Infections Global Clinical Trials Review, H2, 2020

Neisseria meningitidis Infections Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Neisseria meningitidis Infections Global Clinical Trials Review, H2, 2020" provides an overview of Neisseria meningitidis Infections Clinical trials scenario. This report provides top line data relating to the clinical trials on Neisseria meningitidis Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using Glob......
$2500

Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H2, 2020

Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H2, 2020" provides an overview of Non-Alcoholic Steatohepatitis (NASH) Clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis (NASH). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generate......
$2500

Oropharyngeal Cancer Global Clinical Trials Review, H2, 2020

Oropharyngeal Cancer Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Oropharyngeal Cancer Global Clinical Trials Review, H2, 2020" provides an overview of Oropharyngeal Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Oropharyngeal Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical tr......
$2500

Actinic (Solar) Keratosis Global Clinical Trials Review, H2, 2020

Actinic (Solar) Keratosis Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Actinic (Solar) Keratosis Global Clinical Trials Review, H2, 2020" provides an overview of Actinic (Solar) Keratosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Actinic (Solar) Keratosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - ......
$2500

Functional (Non Ulcer) Dyspepsia Global Clinical Trials Review, H2, 2020

Functional (Non Ulcer) Dyspepsia Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Functional (Non Ulcer) Dyspepsia Global Clinical Trials Review, H2, 2020" provides an overview of Functional (Non Ulcer) Dyspepsia Clinical trials scenario. This report provides top line data relating to the clinical trials on Functional (Non Ulcer) Dyspepsia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDa......
$2500

Nasopharyngeal Cancer Global Clinical Trials Review, H2, 2020

Nasopharyngeal Cancer Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Nasopharyngeal Cancer Global Clinical Trials Review, H2, 2020" provides an overview of Nasopharyngeal Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Nasopharyngeal Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinica......
$2500

Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H2, 2020

Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H2, 2020" provides an overview of Pre-Diabetes Impaired Glucose Tolerance Clinical trials scenario. This report provides top line data relating to the clinical trials on Pre-Diabetes Impaired Glucose Tolerance. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports ......
$2500

Schizoaffective Disorder Global Clinical Trials Review, H2, 2020

Schizoaffective Disorder Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Schizoaffective Disorder Global Clinical Trials Review, H2, 2020" provides an overview of Schizoaffective Disorder Clinical trials scenario. This report provides top line data relating to the clinical trials on Schizoaffective Disorder. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Phar......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy